Over the past month, Pfizer’s market capitalization contracted by more than $7 billion as investors reacted to management’s below-expectation guidance for 2026. In the latest trading period, shares slipped nearly 5%, reflecting concerns that revenue growth will slow in the absence of pandemic-era product volumes. Analysts have revised their EPS forecasts for the year down by an average of 5%, signaling caution on top-line momentum.

Pfizer’s oncology franchise delivered mid-single-digit revenue growth in the latest quarter, driven largely by contributions from its Seagen-developed antibody-drug conjugates. However, that increase was partially offset by intensified pricing competition in solid-tumor indications and the expiration of certain royalty agreements. Management highlighted expansion in combination regimens, but noted gross margins in the oncology business contracted by 120 basis points year-over-year.

The company faces an impending patent cliff through 2030, with key growth drivers such as the anticoagulant Eliquis and the breast-cancer therapy Ibrance slated to lose exclusivity. COVID-related product sales, which peaked at over $36 billion globally in 2021, have dwindled to low single-digit billions. Meanwhile, the $7 billion Metsera acquisition has increased Pfizer’s net debt ratio to 0.62, limiting near-term capacity for share buybacks and large-scale M&A.